Connect with us

Nation

IATF eases up on WHO vax trial entries

Published

on

The national pandemic task force has eased mobility restrictions on participants of the World Health Organization’s (WHO) Covid-19 vaccine trials.

Under Resolution 140, the Inter-Agency Task Force for the Management of Emerging Infectious Diseases (IATF-MEID) approved the interzonal movement of trial researchers and affiliate staff.

It means that they can travel to and from areas with different community quarantine classifications.

Meanwhile, trial participants residing in areas under granular lockdowns were permitted to step outside their homes for purposes necessary for clinical study, but they should remain within the area placed under lockdown.

The IATF ratified the resolution Thursday, and copies of the document were shared to the media on Friday morning.

The Covid-19 vaccine trial sponsored by the WHO would be conducted in at least 40 states, including the Philippines.

In general, the study would boost research on the impact of anti-coronavirus jabs and aid world leaders in crafting pandemic-related policies.

For the Philippines, it would be beneficial since it may determine the most effective Covid-19 vaccine suitable for Filipinos and the jab brand which may provide the longest protection against coronavirus.

Some 3,000 Filipinos were eyed to participate in the study, all of whom would be recruited from the top barangays reporting high coronavirus infections.

The cities of Manila, Pasig, Marikina, Makati, Pasay, Muntinlupa City, Cebu and Davao were the eight proposed sites for the WHO trial.

Advertisement

LIKE US ON FACEBOOK

Advertisement
Advertisement